☆ 4.3 Article

Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2021)

Related references

Note: Only part of the references are listed.

Article Allergy

EAACI Biologicals Guidelines-Recommendations for severe asthma

Ioana Agache et al.

Summary: Severe asthma poses significant challenges in management, but targeted treatments with biologicals offer new hope for patients. However, further research is needed on issues such as selection of biologicals, response definition, treatment duration, and cost-effectiveness.

ALLERGY (2021)

Add to Collection

Article Allergy

Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation

Katrien Eger et al.

Summary: The study found that after 2 years of anti-IL-5 treatment, a favorable response was observed in the majority of severe asthma patients, including partial and super responders. Most partial responders showed impaired lung function or uncontrolled sinonasal disease.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Letter Allergy

Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma

Joanne E. Kavanagh et al.

ALLERGY (2021)

Add to Collection

Article Allergy

Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

Luis Perez de Llano et al.

Summary: A valid score was developed to quantify the response to monoclonal antibodies in severe uncontrolled asthma patients, with four core items selected and weighted accordingly. This scoring system allows clinicians to measure the level of response in patients being treated with mAbs, providing valuable guidance in clinical practice.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Critical Care Medicine

Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma A Delphi Study

Carey M. Suehs et al.

Summary: In this study, expert consensus statements were developed on tapering oral corticosteroid (OCS) use in asthma patients through a modified Delphi method. Experts agreed on attempting OCS tapering in patients receiving maintenance therapy, personalizing the tapering rhythm and speed. Areas of nonconsensus were identified, emphasizing the need for further research in certain aspects of OCS use in asthma.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection

Review Respiratory System

How can we minimise the use of regular oral corticosteroids in asthma?

Arnaud Bourdin et al.

EUROPEAN RESPIRATORY REVIEW (2020)

Add to Collection

Article Allergy

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma

Nora Drick et al.

JOURNAL OF ASTHMA AND ALLERGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility

Marc Humbert et al.

RESPIRATORY MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Klaus F. Rabe et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical and economic burden of severe asthma: A French cohort study

Clementine Nordon et al.

RESPIRATORY MEDICINE (2018)

Add to Collection

Article Respiratory System

Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis

Marlene Bloechliger et al.

RESPIRATORY RESEARCH (2018)

Add to Collection

Article Medicine, General & Internal

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma

Parameswaran Nair et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Elisabeth H. Bel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Hector G. Ortega et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Multidisciplinary Sciences

Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review

Rym Boulkedid et al.

PLOS ONE (2011)

Add to Collection

Review Medicine, General & Internal

Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies

Ian P. Sinha et al.

PLOS MEDICINE (2011)

Add to Collection

Article Critical Care Medicine

Shared Treatment Decision Making Improves Adherence and Outcomes in Poorly Controlled Asthma

Sandra R. Wilson et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.